Leptin in Anorexia Nervosa: Not Recommended as Standalone Treatment

Current Evidence Status

Leptin has a potential therapeutic role in specific energy-deprived states like congenital leptin deficiency and hypothalamic amenorrhea, but lacks clinical trial data supporting its use in anorexia nervosa 1, 2
The literature identifies leptin as having a potential therapeutic role in the context of disorders including Relative Energy Deficiency in Sport (REDs) and anorexia nervosa, but this remains theoretical rather than evidence-based 1, 2

Leptin levels are severely reduced in anorexia nervosa patients, falling to 20-30% below baseline during acute starvation 1, 3
In congenital leptin deficiency, metreleptin administration rescues immune dysfunction and reverses starvation-like symptoms including hypothalamic amenorrhea 4

The National Comprehensive Cancer Network recommends megestrol acetate (480-800 mg/day) as a first-line pharmacological option for cancer-related anorexia/cachexia, which improves appetite in 1 of 4 patients and achieves weight gain in 1 of 12, but carries significant risks including thromboembolic events and increased mortality 5, 6, 7
Dexamethasone has similar appetite-stimulating effects with a different toxicity profile 7, 8
Olanzapine is considered for appetite stimulation when quality of life is the priority 5, 6
Combination regimens (medroxyprogesterone + megestrol acetate + eicosapentaenoic acid + L-carnitine + thalidomide) produce better outcomes than single agents for cancer-related anorexia/cachexia 5, 6